These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 7759558

  • 1. Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes.
    Murray GJ, Oliver KL, Jin FS, Brady RO.
    J Cell Biochem; 1995 Feb; 57(2):208-17. PubMed ID: 7759558
    [Abstract] [Full Text] [Related]

  • 2. Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupffer cells.
    Murray GJ, Jin FS.
    J Histochem Cytochem; 1995 Feb; 43(2):149-58. PubMed ID: 7822772
    [Abstract] [Full Text] [Related]

  • 3. Measurement of lysosomal glucocerebrosidase activity in mouse liver using a fluorescence-activated cell sorter assay.
    Chan KW, Waire J, Simons B, Karey K, Fung J, Copeland D, Andrews L.
    Anal Biochem; 2004 Nov 15; 334(2):227-33. PubMed ID: 15494128
    [Abstract] [Full Text] [Related]

  • 4. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D.
    Plant Biotechnol J; 2007 Sep 15; 5(5):579-90. PubMed ID: 17524049
    [Abstract] [Full Text] [Related]

  • 5. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ.
    FEBS J; 2006 Sep 15; 273(17):4082-92. PubMed ID: 16934036
    [Abstract] [Full Text] [Related]

  • 6. Status of enzyme replacement therapy for Gaucher disease.
    Brady RO, Barranger JA, Gal AE, Pentchev PG, Furbish FS.
    Birth Defects Orig Artic Ser; 1980 Sep 15; 16(1):361-8. PubMed ID: 7004519
    [Abstract] [Full Text] [Related]

  • 7. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells.
    Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM.
    Eur J Biochem; 1996 Apr 15; 237(2):344-9. PubMed ID: 8647071
    [Abstract] [Full Text] [Related]

  • 8. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.
    Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, Winfield S, Zablocka B, Sidransky E, Martin BM, Huang SP.
    Nature; 1992 Jun 04; 357(6377):407-10. PubMed ID: 1594045
    [Abstract] [Full Text] [Related]

  • 9. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.
    Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P.
    Cell; 2007 Nov 16; 131(4):770-83. PubMed ID: 18022370
    [Abstract] [Full Text] [Related]

  • 10. Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells.
    Murray GJ.
    Methods Enzymol; 1987 Nov 16; 149():25-42. PubMed ID: 3695962
    [Abstract] [Full Text] [Related]

  • 11. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease.
    Schmitz M, Alfalah M, Aerts JM, Naim HY, Zimmer KP.
    Int J Biochem Cell Biol; 2005 Nov 16; 37(11):2310-20. PubMed ID: 15982918
    [Abstract] [Full Text] [Related]

  • 12. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease.
    Lonser RR, Walbridge S, Murray GJ, Aizenberg MR, Vortmeyer AO, Aerts JM, Brady RO, Oldfield EH.
    Ann Neurol; 2005 Apr 16; 57(4):542-8. PubMed ID: 15786474
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease.
    Mistry PK, Wraight EP, Cox TM.
    Lancet; 1996 Dec 07; 348(9041):1555-9. PubMed ID: 8950883
    [Abstract] [Full Text] [Related]

  • 14. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D.
    Toxic Rep Ser; 1995 Apr 07; 30():1-G5. PubMed ID: 12209194
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.
    van Weely S, van den Berg M, Barranger JA, Sa Miranda MC, Tager JM, Aerts JM.
    J Clin Invest; 1993 Mar 07; 91(3):1167-75. PubMed ID: 8450045
    [Abstract] [Full Text] [Related]

  • 17. Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model.
    Lamghari M, Barrias CC, Sá Miranda C, Barbosa MA.
    Blood Cells Mol Dis; 2005 Mar 07; 35(3):348-54. PubMed ID: 16125984
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Enzyme replacement therapy in type 1 Gaucher's disease].
    Aggio MC, Fernández V, Marcilese M.
    Medicina (B Aires); 1994 Mar 07; 54(2):140-4. PubMed ID: 7997130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.